Table 1.
Recent literature on the impact of Luminex-detected pretransplant HLA antibodies (ab) on lung transplant outcome
| Reference | Patients,n | Study period | MFI | Anti-HLA ab | DSA | AMR | BOS | 1-year survival | XM | Risk predictor | Patient selection |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Smithet al.[8], 2014 | 425 | 1991–2003 | >5,000 | 63 | 12/27 | na | ns | ↓ | CDC | DSA (MFI >5,000) and DSA+C4d | Retrospective, single center |
| C4d+ | 9/27 | ↓↓ | |||||||||
| >2,000–5,000 | 7/27 | ns | |||||||||
| <2,000 | 8/27 | ns | |||||||||
| Kimet al. [66], 2014 | 224 (waiting list), 126 (transplanted) | 2008–2012 | >3,000 | 77 | na | ↑ | na | ns | CDC | DSA (MFI >3,000) for AMR | Retrospective, single center |
| >1,000–3,000 | 54 | ns | na | ns | |||||||
| Chinet al. [42], 2015 | 195 | 2008–2012 | >500 | 87 | 56 | ns | ns | ns | CDC | – | Retrospective, single center |
| Brugière et al. [43], 2013 | 56 | Before 2008 | >300 | 47 | 18 | na | ↑ (for class II ab) | na | – | DSA class II | Retrospective, single center |
DSA, donor-specific HLAantibodies;AMR, antibody-mediated rejection; BOS, bronchiolitis obliterans syndrome; MFI, mean fluorescence intensity; ns, nonsignificant difference; na, not applicable; XM, crossmatch.